Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors

Biomarkers for treatment with immune checkpoint inhibitors. Where are we now?

Date

19 Sep 2021

Session

GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors

Topics

Immunotherapy

Tumour Site

Endometrial Cancer;  Colon and Rectal Cancer

Presenters

Josef Rüschoff

Authors

J. Rüschoff

Author affiliations

  • DRK-Kliniken Nordhessen Gemeinnützige GmbH, 34121 - Kassel/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introduction

Presenter: Thierry André

Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.